Delayed
OTC Markets
11:25:39 08/03/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.1855
USD
|
-11.68%
|
|
-.--%
|
-19.35%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
29.55
|
6.278
|
5.183
|
10.63
|
6.854
|
3.139
|
Enterprise Value (EV)
1 |
29.44
|
6.577
|
5.63
|
11.2
|
7.604
|
4.015
|
P/E ratio
|
-7.47
x
|
-4.03
x
|
-7.74
x
|
-9.96
x
|
-9.25
x
|
-3.94
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
29.8
x
|
72.8
x
|
78.3
x
|
27.1
x
|
143
x
|
43.5
x
|
FCF Yield
|
3.36%
|
1.37%
|
1.28%
|
3.69%
|
0.7%
|
2.3%
|
Price to Book
|
276
x
|
-12.4
x
|
-7.46
x
|
-9.64
x
|
-5.36
x
|
-2.11
x
|
Nbr of stocks (in thousands)
|
12,850
|
13,080
|
13,290
|
13,290
|
13,440
|
13,650
|
Reference price
2 |
2.300
|
0.4800
|
0.3900
|
0.8000
|
0.5100
|
0.2300
|
Announcement Date
|
25/03/19
|
30/03/20
|
31/03/21
|
11/03/22
|
31/03/23
|
15/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.905
|
-1.516
|
-0.5537
|
-0.802
|
-0.6296
|
-0.6437
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-3.931
|
-1.547
|
-0.663
|
-1.068
|
-0.7335
|
-0.7893
|
Net income
1 |
-3.931
|
-1.547
|
-0.663
|
-1.068
|
-0.7335
|
-0.7893
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3078
|
-0.1190
|
-0.0504
|
-0.0804
|
-0.0552
|
-0.0583
|
Free Cash Flow
1 |
0.9888
|
0.0903
|
0.0719
|
0.4136
|
0.0531
|
0.0923
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/03/19
|
30/03/20
|
31/03/21
|
11/03/22
|
31/03/23
|
15/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
0.3
|
0.45
|
0.57
|
0.75
|
0.88
|
Net Cash position
1 |
0.12
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
0.99
|
0.09
|
0.07
|
0.41
|
0.05
|
0.09
|
ROE (net income / shareholders' equity)
|
-6,164%
|
772%
|
110%
|
119%
|
61.6%
|
57%
|
ROA (Net income/ Total Assets)
|
-1,812%
|
-594%
|
-383%
|
-1,081%
|
-2,064%
|
-23,068%
|
Assets
1 |
0.217
|
0.2604
|
0.1733
|
0.0988
|
0.0355
|
0.003422
|
Book Value Per Share
2 |
0.0100
|
-0.0400
|
-0.0500
|
-0.0800
|
-0.1000
|
-0.1100
|
Cash Flow per Share
2 |
0.0100
|
0.0100
|
0
|
0
|
0
|
0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/03/19
|
30/03/20
|
31/03/21
|
11/03/22
|
31/03/23
|
15/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -19.35% | 2.53M | | +24.05% | 47.02B | | +49.73% | 41.86B | | +0.25% | 41.76B | | -4.27% | 28.8B | | +12.70% | 26.05B | | -21.27% | 19.15B | | +4.00% | 12.55B | | +31.50% | 12.34B | | -3.77% | 11.82B |
Other Biotechnology & Medical Research
|